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Abstract: Despite significant advances in both our understanding and the 
treatment of cancer, the disease remains one of high mortality and 
morbidity in all species.  Increase in survival times in human cancer 
have increased significantly in the past 25 years but most of these 
increases have been through small incremental changes.  For some cancers, 
e.g. pancreatic cancer, survival times have not increased significantly 
in over 100 years.  In veterinary oncology, we have seen major shifts in 
the management of cancer in companion animals.  Increased availability of 
specialist centres, coupled with changing attitudes in owners and 
veterinarians, have meant that we have seen an improvements in veterinary 
cancer care borne from market pressures and increased awareness and 
understanding.  In this review piece we will look at the changing face of 
cancer biology over the past 25 years, and consider the barriers to 
clinical progress in veterinary medicine.  Finally, we will share an 
optimistic view of the future and the prospect for greater control over 
this devastating disease. 
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Abstract 8 
Despite significant advances in both our understanding and the treatment of 9 
cancer, the disease remains one of high mortality and morbidity in all species.  10 
Increase in survival times in human cancer have increased significantly in the 11 
past 25 years but most of these increases have been through small incremental 12 
changes.  For some cancers, e.g. pancreatic cancer, survival times have not 13 
increased significantly in over 100 years.  In veterinary oncology, we have seen 14 
major shifts in the management of cancer in companion animals.  Increased 15 
availability of specialist centres, coupled with changing attitudes in owners and 16 
veterinarians, have meant that we have seen an improvements in veterinary 17 
cancer care borne from market pressures and increased awareness and 18 
understanding.  In this review piece we will look at the changing face of cancer 19 
biology over the past 25 years, and consider the barriers to clinical progress in 20 
veterinary medicine.  Finally, we will share an optimistic view of the future and 21 
the prospect for greater control over this devastating disease. 22 
  23 
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Introduction 24 
According to data from Cancer research UK (CRUK), in 2012 there were 14.1 25 
million new human cancer diagnoses world-wide and 8.2 million deaths2.  26 
Reducing cancer mortality is clearly an international priority. However, despite 27 
incremental improvements in cancer therapies, the disease remains one of high 28 
morbidity and mortality in all species (Argyle and Blacking, 2008).  29 
Improvements in public health and the control of infectious disease have 30 
compounded the problem making cancer the world’s leading cause of death in 31 
humans. In addition, cancer has a huge impact on the economy through loss of 32 
productivity, loss of years of life, and cost related to treatment.  According to 33 
American Cancer Society the total economic impact of premature death and 34 
disability from cancer worldwide was $895 billion in 20083.  This figure 35 
represents 1.5% of world’s GDP and does not include direct cost of treating 36 
cancer.  According to Murphy and Topel (2003), a 10% reduction in cancer 37 
deaths worldwide would be worth $4.7 trillion in social value. 38 
 39 
Cancer in veterinary species can have two broad consequences.  Cancer in 40 
livestock species can have a major economical impact, especially an infectious 41 
cause of cancer, e.g. Marek’s disease in poultry, or Bovine Leukosis in cattle, 42 
causing significant loss of production.  In contrast, the major impact on 43 
companion animals relates to their long-term health and their relationship with 44 
their owners.  Although true epidemiological data worldwide is lacking in 45 
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veterinary medicine, we estimate that the incidence of cancer in dogs is around 1 46 
in 3 (and 1 in 4 to 5 in cats) (Pang, et al., 2009).  This is not dissimilar to man and 47 
with a similar pattern of improved control of infectious disease pushing cancer 48 
up the league table of significant causes of death.  Cancer treatments and (and 49 
consequently cancer treatment centres) have increased significantly in the last 50 
20 years.  Cancer treatments have become “accepted clinical practice” and 51 
owners now have much broader access to facilities such as external beam 52 
radiation.  The control of cancer and cancer treatment-related side effects is 53 
much improved with the development of new drugs (e.g. NK-1 inhibitors for 54 
nausea) and we have seen the first targeted drugs for veterinary oncology being 55 
approved and launched (e.g. London et al., 2009).   We have learnt a great deal 56 
about the biology of cancer in dogs and cats in the last two decades.  This has 57 
been supported by the publications of species genomes which has also created, 58 
in small part, the tool box required to understand this disease at the genetic level 59 
and also investigate the clear breed predispositions for certain types of cancer 60 
(Ostrander and Kuglyak, 2000).  However, as with human medicine, we still 61 
recognize cancer as the leading chronic disease and one of the biggest causes of 62 
death in companion animals (Argyle and Blacking, 2008). 63 
 64 
The hallmarks of cancer 65 
It is very difficult to define what a cancer is and to put that definition into a 66 
clinical context.  If one considers that homeostasis is fundamental to health, then 67 
cancer can be considered in terms of a breakdown in the homeostatic 68 
mechanisms that control cell growth, cell division and cell death.  Consequently, 69 
we have to deal clinically with a group of cells, who have lost control of intrinsic 70 
cell growth and division, and can, under certain circumstances, spread 71 
(metastasize) to distant sites in the body.  It is often this last critical step that can 72 
ultimately lead to the death of the patient. 73 
 74 
Our traditional understanding of how a cancer develops comes from studies and 75 
mathematical modeling in diseases such as colon cancer in man (e.g. Little and 76 
Wright, 2003) and is built upon seminal work by Nordling (1953) and Knudson 77 
(1971).  Colon cancer is one of the diseases that has allowed clinicians and 78 
scientists to model multistage carcinogenesis, demonstrating the changes from 79 
polyp formation to metastatic colon cancer.  This model has been central to 80 
identifying key changes in cells that give rise to the malignant phenotype, from 81 
an initiation step (first fundamental genetic change to the DNA of the cell), and 82 
including the multiple stochastic genetic “hits” that the cell acquires to become a 83 
cancer cell (Figure 1).   What is clear is that cancer is a disease that affects the 84 
fundamental genetic material (DNA) of a cell, the phenotype of which is passed to 85 
the daughter cell.  The discovery of viruses that cause cancer laid the foundation 86 
for the discovery and description of oncogenes and tumour suppressor genes 87 
(Argyle and Blacking, 2008).  These genes and their protein products are 88 
intimately involved with cell cycle regulation.  Oncogenes are the cell’s 89 
“accelerator pedal” and drive cell growth and division.  Tumour suppressors are 90 
the cells “brake pedal” and add a level of control to the cell cycle.  Cancers often 91 
contain major changes in these genes, which cause a breakdown in homeostasis, 92 
making them significant targets for therapy. 93 
 94 
The almost exponential advances in molecular biology over the past 25 years 95 
have facilitated the dissection of these pathways and the development of drugs 96 
to target them.   For a disease for which clinical control has been centred on the 97 
crudest of treatments (cancer chemotherapy), the advent of these discoveries 98 
sparked a fiercely competitive search for drugs that could target specific 99 
pathways that are known to be dysregulated in cancer. 100 
 101 
However, what has become apparent, are the myriad of “altered” pathways and 102 
genetic changes in cancer cells that present a picture of a far more complex 103 
syndrome at the cellular level.  In 2000 and again in 2011, Hannah and Weinberg 104 
made a significant attempt to distil the cancer phenotype into the acquisition of 105 
fundamental characteristics.  The initial six cancer traits defined in the 2000 106 
paper were added to in 2011, when the authors expanded the model to include 107 
evasion of the immune system and the acquisition of abnormal metabolic 108 
pathways (Figure 2).   These traits are common across cancer phenotypes and 109 
offer the possibility of defining opportunities for biomarker discovery or 110 
therapeutic intervention.  However, as we have developed the tools to define 111 
these pathways in detail, explore multiple genes in multiple cell types, define 112 
genetic and protein profiles, the complexity of the cancer cell seems to expand.  113 
As an added complication, both the cancer niche (microenvironment) and the 114 
epigenome have come to the foreground as being major players in cancer 115 
initiation and progression. 116 
 117 
Challenging the traditional model of cancer development 118 
In the last 10 years we have seen significant challenge to the traditional 119 
stochastic model of cancer development (described above).  In many ways the 120 
simple model from initiation to metastatic cell (requiring the acquisition of 121 
multiple hits over time), did not fit well with our understanding of tissue and cell 122 
turnover in organ systems.  An evolving model (cancer stem cell model) treats 123 
the cancer as an “organ system” where the bulk tumour population is driven by a 124 
small number of cancer stem cells (Blacking et al., 2007).  This model has not 125 
been universally accepted (and may be different for different cancer types) but 126 
has gained significant ground in recent years.  The clinical significance of this is 127 
immense as it gives the fundamental basis for tumour heterogeneity and 128 
suggests that a cancer is driven by cells that have striking resistance to 129 
conventional anti-cancer drugs.  Cancer stem cells have been identified in cat and 130 
dog cancers that have significant resistance to conventional cancer drugs, 131 
radiation and have altered responses to DNA damage (Wilson et al., 2008; Pang 132 
et al., 2011, 2013 and 2015).  The true classification of these cells is still 133 
controversial and there is still no universal cell marker for purification of these 134 
cells (Blacking et al., 2012).  However, what is clear, is that cancers contain sub-135 
populations of cells that are highly resistant to conventional therapies and 136 
contribute significantly to tumour heterogeneity and treatment failure (Figure 137 
3). 138 
 139 
Genes, dreams and cancer signatures 140 
From a position over 20 years ago, when we could only look at single pathways 141 
or genetic changes in cancer cells in a stepwise fashion, we have moved to a 142 
position when we can examine thousands of genes in a cancer sample using gene 143 
array “chips”.  Initially, these were expensive technologies but the cost has 144 
plummeted in recent years, accompanied by newer technologies such as high 145 
throughput sequencing and RNA sequencing (RNA-seq).  RNA-seq uses Next 146 
Generation Sequencing (NGS) to rapidly analyze the changing transcriptome in a 147 
cancer cell.  This has been coupled with cost-effective and rapid ways of 148 
examining the cancer protein profile, its secretome, the metabolome and many of 149 
the epigenetic mechanisms operating at the cellular level.  These technologies in 150 
cancer discovery have been used to: 151 
1. Identify common cancer signatures across phenotypes 152 
2. Identify potential targets for drug development 153 
3. Identify “driver” and “passenger” mutations to assist drug discovery 154 
4. Identify biomarkers of cancer for early detection 155 
5. Identify specific pathways that may be druggable. 156 
These technologies have also become affordable enough to be used to study 157 
companion animal tumours, both in their own right and as models for human 158 
disease (e.g. Mudaliar, et al., 2013; Pang et al., 2014).  There is little doubt that 159 
the information obtained from these studies is proving incredibly useful.  160 
However, the challenge is still to be able to translate discovery into practical 161 
solutions for patients.   162 
 163 
Why no cure? 164 
We have experienced an exponential growth in understanding of cancer biology 165 
in the past 25 years.  However, although we have seen some shift in survival 166 
times and improved mortality in humans, we have not seen the paradigm shift 167 
that the new cancer technologies promised.   Pragmatically, this should not be a 168 
surprise considering the complexity of the disease, but it is worth considering a 169 
number of issues that have arisen and how these may be overcome: 170 
 171 
Data, data and more data:  Our ability to dissect the cancer genome, proteome 172 
and metabolome has become incredibly refined and affordable.  However, our 173 
ability to analyze the sheer volume of data (bioinformatics) has not kept pace 174 
with our ability to derive it.  Much effort is now underway to expand our 175 
bioinformatics capability to keep pace with the information being gathered and 176 
to be able to use that information in a clinically relevant way.    It is absolutely 177 
essential that cancer researchers and oncologists do not work in isolation but 178 
work across disciplines with bioinformaticians, mathematicians, engineers, and 179 
computer scientists, so we can both effectively mine and put some context to the 180 
enormity of the biological and clinical data that can now be generated. 181 
 182 
Human colorectal cancer in man exemplifies the challenges that we face as 183 
cancer researchers and oncologists.  Although colorectal cancer (CRC) was 184 
among the first solid tumors to undergo molecular profiling, the clinical 185 
translation of this knowledge into effective therapies has been impeded by the 186 
startling level of complexity and heterogeneity revealed among these tumours.  187 
Despite approval of several new drugs in recent years, the success of these and 188 
other agents in development has been stifled by the complex nature of CRC. It 189 
has become clear that the only way forward requires a paradigm shift toward 190 
integrative analyses that encompass multiple classes of genomic aberrations and 191 
consensus classification of CRC based on genomic data to facilitate more effective 192 
management of this disease.  193 
 194 
Darwinian evolution:  What has become very clear is that any “omic signature” 195 
gained for a specific cancer or biological sample reflects a simple snapshot in 196 
time for that sample.  Expression of genes and proteins can rapidly change in a 197 
rapidly evolving tumour system and can be a reflection of inherent changes in 198 
the cell or as a result of changes in the cancer microenvironment (e.g. Greaves 199 
and Maley, 2012).   This is hugely challenging as we may be identifying drug 200 
targets that are only transitory in nature or are subject to intense selection 201 
pressures.  In addition to selection, there is also increasing evidence of 202 
significant cell plasticity in tumours (adaptation) that may also change the 203 
potential of druggable targets (Faurobert et al., 2015).  It is clear that 204 
heterogeneity within tumours contributes significantly to treatment failure, but 205 
this heterogeneity is itself very dynamic and difficult to document in real-time 206 
(Brooks et al., 2015). 207 
 208 
One of the major reasons for treatment failure in human and veterinary patients 209 
is the development of drug resistance.  Drug resistance developing during 210 
treatment with conventional chemotherapy drugs is well documented in human 211 
and veterinary medicine and has been a subject of significant research 212 
investment.  The development of targeted drugs which “hit” a specific pathway 213 
or “driver mutation” has been seen as a major breakthrough in cancer drug 214 
development, exemplified by the plethora of small molecules that have been 215 
developed to target the cancer kinome.  Tyrosine kinases have been a hotly 216 
researched area of drug development as changes (e.g. mutations) in kinase 217 
pathways represent major drivers of malignancy (Bavcar and Argyle, 2012).  218 
Imatinib (Gleevec) is a small molecule inhibitor that targets Receptor Tyrosine 219 
Kinases (RTK) and was one of the fastest cancer drugs to reach the market (from 220 
initial discovery to clinical licensing), being used extensively in human 221 
leukaemia.  However, as with conventional drugs, the selection pressure created 222 
by using one single drug supports the development of drug resistance in certain 223 
groups of patients (Bixby and Talpaz, 2011).  The development of Imatinib has 224 
been followed by the development of second and third generation RTK inhibitors 225 
to overcome the inevitable acquisition of resistance.  However, as we have 226 
described above, cancer is far more complex and just targeting one driver 227 
mutation in a tumour is probably insufficient.  It is likely that the greatest 228 
success in cancer control is going to be achieved through targeting multiple 229 
pathways in cancer and also playing close attention to tumour 230 
microenvironment and the role of epigenetic drivers in cancer. 231 
 232 
The concept of tumour evolution also applies to how the body’s immune system 233 
responds to cancer and how successful immunotherapy is in cancer patients 234 
(Figure 4).  As with targeted drug therapy, advances in immunotherapy have 235 
resulted in remarkable clinical responses in some human patients (Raposo, et al., 236 
2015).  However, one of the biggest challenges in cancer therapeutics is the 237 
development of resistant disease and disease progression on or after therapy.  238 
For patients with metastatic cancer, conventional chemotherapy (plus or minus 239 
targeted therapies) has not proven curative.  However, there is significant 240 
clinical trial data in human patients to suggest that immunotherapy has the 241 
potential to achieve long lasting remissions in patients with metastatic disease.  242 
However, as with some of the targeted therapies, immune-selective pressure for 243 
resistant tumour cells clearly exists (Restifo et al., 2016).  It is likely that this 244 
resistance derives from the type of Darwinian evolution described above (e.g. 245 
selection pressure on the tumour giving rise to selective loss of components of 246 
MHC).  In addition, tumour cells may acquire resistance through adaptation in 247 
response to interactions with immune cells.  One mechanism that has gained 248 
prominence recently has been the tumour cell expression of programmed cell 249 
death protein (PD1) and its ligand (PDL1), which serve to down regulate the 250 
anti-tumour immune response (Mamalis, et al., 2014).  Drugs and monoclonal 251 
antibodies targeting this “immune checkpoint” are the subject of intense 252 
research and human clinical trials. 253 
 254 
“Big bang theory” and tumour heterogeneity:  Recent studies of colon cancer 255 
utilizing genomic data and mathematical modeling, suggest that the majority of 256 
genetics changes and intratumoural heterogeneity (ITH) actually occurs very 257 
early on in tumour evolution once the malignant phenotype of the cell has been 258 
achieved (Sottoriva et al., 2016).   This also suggests that a tumour’s ability to 259 
invade and metastasize are programmed early in development rather than 260 
acquired by selective forces.  This has major implications for drug and biomarker 261 
discovery as it suggests that the formation of new driver mutations during 262 
tumour evolution are not as common as once considered.  It also means that 263 
some tumours are just “born bad” whatever we do to them 264 
 265 
The lack of good model systems:  Rodent xenograft models have been the 266 
traditional test bed for new anti-cancer therapies. However treatment responses 267 
in rodents frequently do not translate into benefit in patients (Pang and Argyle, 268 
2009). This mismatch is multifactorial but broadly reflects major differences in 269 
tumour biology and pathophysiology and lack of tools to measure critical 270 
changes in the tumour microenvironment that drive tumour growth and 271 
response to treatment. Basic cancer research, combined with xenograft models 272 
have made great progress in our understanding of the mechanisms that underlie 273 
the development of human cancer and in cancer detection but the current pre-274 
clinical models are too slow, too costly and lack predictability for the efficient 275 
translation into new cancer treatments. Similarly, small animals are insufficient 276 
for the development of new technology for detecting early cancers. Mouse 277 
models have played an important role in identifying the molecular pathways of 278 
cancer but the uncertainty of artificial tumours in mice to foresee the clinical 279 
outcome of new treatments and their insufficiency for testing new imaging 280 
technology have become ever tighter bottlenecks for bringing new treatments 281 
and technology to the benefit of the patients. Hence, new pre-clinical models to 282 
more rapidly translate advances in basic cancer research, diagnostics and 283 
treatment into the clinic are of most urgent need. 284 
 285 
A cause for optimism? 286 
Our ability to dissect the cancer genome and all of its components has far 287 
exceeded our ability to analyze and understand the data.  We can therefore 288 
conclude that the complexity of the cancer cell is currently impeding our ability 289 
to define and produce better treatments and better outcomes for patients.   As a 290 
community involved in cancer research, clinical oncology or both, what can we 291 
do to drive progress and is there cause for optimism?   The simple answer to this 292 
is that there is great deal we can do and there is definitely cause for optimism in 293 
both human and veterinary oncology.  We are seeing a renaissance and 294 
rejuvenated interest in conventional treatments such as radiotherapy, we are 295 
developing new and innovative ways to study cancer, and more than ever before 296 
we are exploring cancer without any species boundaries.  Below is not an 297 
exhaustive list, but offers an optimistic view of veterinary and human oncology: 298 
 299 
Advances in conventional therapies:  Patient responses to conventional 300 
treatments in veterinary oncology have become more predictable as we gain 301 
greater experience in managing common cancer types.  However, for diseases 302 
such as Lymphoma, we have probably reached a “watershed” in terms of our 303 
ability to significantly alter disease free interval and survival times with the 304 
drugs we have available (Comazzi, et al., 2015).   This is also considering our 305 
appropriate need in veterinary oncology to maintain quality of life in our 306 
patients.  New cancer chemotherapy dugs are few and far between and we rely 307 
on orphan drugs from human medicine to fill the significant pharmacy gap that 308 
we have in veterinary oncology.  We have, however, seen a major renaissance in 309 
radiation oncology, especially in terms of availability.  We have gone beyond 310 
course fractionated regimes and embraced radiotherapy plans and prescriptions 311 
with curative intent.  This is only set to increase with advances in planning 312 
systems and increased use an availability of IMRT (Intensity Modulated 313 
Radiotherapy) and SBRT (Stereotactic Body Radiotherapy) (Feng, et al., 2015 314 
and 2016) 315 
 316 
Advances in imaging: In recent years there has been a tremendous 317 
improvement in imaging technologies and access to these technologies.  We have 318 
been able to go beyond radiographic analysis and been able to take advantage of 319 
the imaging resolutions afforded by Computerized Axial Tomography (CT) and 320 
Magnetic Resonance Imaging (MRI).   While these modalities are improving the 321 
imaging resolution in terms of anatomy, functional imaging (e.g. Positron 322 
Emission Tomography (PET)) is set to become more available and will be a 323 
major diagnostic modality, especially for cancer patients and for the 324 
identification of primary and metastatic lesions.  The cost and availability of new 325 
modalities is coming down and we can expect that these will become a common 326 
part of the cancer staging process both in primary care and referral centres. 327 
 328 
Drug and device development:  New drug development for cancer in 329 
companion animals is hugely challenging, not least for even the biggest 330 
pharmaceutical companies.  Since the launch of toceranib (Palladia) and 331 
masitinib (Masivet), there have been no new “second generation” drugs as seen 332 
in human oncology.  The indications for both of these drugs (as dictated by the 333 
license arrangement) was somewhat limited and was not the panacea for cancer 334 
that some may have wanted or predicted.  We are still (as a community) learning 335 
a lot about how to use these drugs either alone or in combination with 336 
conventional drugs, and it is possible that their use will become more 337 
widespread in these scenarios.  Dogs do develop resistance and with few follow-338 
on options (no second generation drugs), their use can become limited in some 339 
patients.  However, for the veterinary pharmaceutical industry the financial 340 
margins on these drugs and the expense of getting them to market are a huge 341 
challenge, especially when you consider the size of the market.  The veterinary 342 
oncology market is a mere fraction of the $100 billion dollar human cancer drug 343 
market.   A secondary route to market could involve using drugs developed for 344 
human oncology, as long as pharma can tolerate the potential price differential 345 
between what they can charge for a human drug and what can be reasonably 346 
charged for a veterinary drug. 347 
 348 
However, instead of human and veterinary oncology drug development 349 
operating in parallel, there is a model that transcends the species boundaries to 350 
allow combined drug development.   Rodent xenograft models have been the 351 
traditional test bed for new anti-cancer therapies. However treatment responses 352 
in rodents frequently do not translate into benefit in patients. This mismatch is 353 
multifactorial but broadly reflects major differences in tumour biology and 354 
pathophysiology and lack of tools to measure critical changes in the tumour 355 
microenvironment that drive tumour growth and response to treatment. Basic 356 
cancer research, combined with xenograft models have made great progress in 357 
our understanding of the mechanisms that underlie the development of human 358 
cancer and in cancer detection but the current pre-clinical models are too slow, 359 
too costly and lack predictability for the efficient translation into new cancer 360 
treatments (Pang and Argyle, 2009). Similarly, small animals are insufficient for 361 
the development of new technology for detecting early cancers. Mice models 362 
have played an important role in identifying the molecular pathways of cancer 363 
but the uncertainty of artificial tumours in mice to foresee the clinical outcome of 364 
new treatments and their insufficiency for testing new imaging technology have 365 
become ever tighter bottlenecks for bringing new treatments and technology to 366 
the benefit of the patients. Hence, new pre-clinical models to more rapidly 367 
translate advances in basic cancer research, diagnostics and treatment into the 368 
clinic are of most urgent need. Spontaneous or naturally occurring tumours in 369 
dogs and cats share important molecular, histopathological and therapeutic 370 
characteristics with corresponding human disease and, thus, provide cancer 371 
models that are closer to man than rodent models (Rowell et al., 2011; Shearin 372 
and Ostrander 2010; Khanna et al., 2006; Pang and Argyle, 2009). Clinical data 373 
derived from trials in spontaneous tumours in domestic animals could serve not 374 
only to improve animal health but serve as an important link between basic 375 
cancer research and human and veterinary clinical trials.  While much emphasis 376 
has been placed recently on translation of biology into clinical practice, this kind 377 
of approach aims to create a platform of inderdisciplinarity that supports both 378 
translation, and transformation of clinical cancer practice, offering the greatest 379 
opportunity for Impact.  This would include: 380 
1. Reducing the time taken for a therapeutic targets to be translated into clinical 381 
benefit 382 
2. Reducing the high costs of therapeutic development 383 
3. Increasing the predictability of human pre-clinical models. 384 
This concept can go beyond drug development and also be applied to other 385 
aspects of cancer research such as the development of medical devices.  As an 386 
example, IMPACT (Implantable Microsystems for Personalized Anti-cancer 387 
Therapy)4 is a collaboration between engineering, veterinary oncology, human 388 
oncology, chemistry, and social science, to develop implantable sensors that are 389 
able to detect changes in tumour microenvironment in real time.   For example, if 390 
we can detect subtle changes in hypoxia in real-time during radiotherapy, then 391 
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treatment plans can be adjusted rapidly to compensate and improve clinical 392 
outcomes in patients.  This project aims to develop a platform technology that 393 
could be applied to a wide range of cancers and perhaps ultimately being able to 394 
deliver anti-cancer drugs locally, and in a controlled way. 395 
Monoclonal antibodies for diagnosis and treatment:  The development of 396 
small molecules to target RTK pathways and driver mutations was considered to 397 
be one of the major breakthroughs in cancer research.  However, monoclonal 398 
antibodies have now far exceeded small molecules in terms of the market share 399 
of biologics being used in cancer treatments.  Some of the advantages of 400 
monoclonal antibody therapeutics over conventional drugs are high specificity, 401 
precise mode of action and long half-life, which favours infrequent dosing of the 402 
antibody. Monoclonal antibodies have been developed for a number of cancer 403 
targets including Anti-CD20 (B cell Lymphoma, Anti-EGFR (multiple targets 404 
including head and neck cancer) and anti-VEGFR (Multiple cancer types 405 
targeting angiogenesis) (reviewed by Xin et al., 2013).  However, the use of 406 
“human” monoclonal antibodies in veterinary oncology is usually not feasible 407 
due to the development of an immune response to foreign protein.  Recently new 408 
techniques have allowed the development of species-specific  (e.g. caninized) 409 
monoclonal antibodies.  A full description of this technology is outwith the scope 410 
of this review but can be found by Breiro et al., 2016).   Caninized anti-CD20 is in 411 
clinical use and a pipeline of discovery through to clinical application is being 412 
developed by a number of companies in the veterinary arena (Jain et al., 2016).  413 
This is a truly exciting prospect, as it will deliver new and affordable reagents to 414 
the veterinary oncology community. 415 
A renaissance for immunotherapy:  Immunotherapy for cancer in all species 416 
has followed a continuous sine wave varying between optimism and pessimism.  417 
Immunotherapy has become one of oldest forms of cancer treatment, the aim 418 
being to harness the body’s immune system to target a tumour with altered “self 419 
proteins”.   While immunotherapy has achieved considerable success in some 420 
patients, we still do not fully understand why some patients will mount a 421 
positive anti-tumour response, and others do not.  This is also confounded by 422 
Darwinian selection pressures (described above) and the development of 423 
adaptive responses to immunotherapy.  As with our understanding of the 424 
molecular events in cancer, our understanding of immunity is also exponentially 425 
increasing.  There is particular cause for optimism currently around the 426 
dissection of the pathways involved in adaptive responses and a good example of 427 
this is the PD1/PD1L axis.  Programmed death-1 (PD-1) is expressed on the 428 
surface of immune cells, and programmed death ligand-1 (PD-L1) is often 429 
expressed on cancer cells. When PD-1 and PD-L1 bind, this results in suppression 430 
of T cell activity and reduction of T cell-mediated cytotoxicity (Robert et al. 431 
2014). Thus, PD-1 and PD-L1 are immune down-regulators or immune 432 
checkpoint “off switches” (Mamalis et al., 2014), which allow cancer cells to 433 
evade immune destruction.  Anti-PD1 and PD1L drugs and monoclonal antibody 434 
development have been intensely pursued by the pharmaceutical and academic 435 
communities as a mechanism for immune-modulating cancer patients (e.g. in 436 
malignant melanoma).  Whereas previous immunotherapies have focused on 437 
promoting anti-tumour immunity, this approach tries to inhibit immune 438 
checkpoints that protect cancers from immune destruction.  Alone, this therapy 439 
may be insufficient to offer complete cures, but combining it with other 440 
modalities or immunotherapies may offer a significant advantage over current 441 
treatments. 442 
Big data and precision medicine:  The development of the appropriate 443 
reagents for mining veterinary genomes, proteomes and metabolomes is rapidly 444 
expanding.  Coupled with this is the reduction in costs associated with 445 
sophisticated genomic and proteomic analysis.  With this will come an increased 446 
ability to: 447 
1. Mine veterinary cancer genomes and proteomes using multiple samples. 448 
2. Potentially identify biomarkers for the early detection of cancer, prediction of 449 
treatment success or the early detection of treatment failure. 450 
These technologies are already is use and proving useful for dissecting the 451 
complexity of cancer.  However, with this we must embrace the importance of 452 
bioinformatics, statistics and mathematical modeling if we are going to take full 453 
advantage of the amount of data we are generating.  This must also be linked 454 
with appropriate clinical data from the field so we can develop appropriate 455 
algorithms that will be useful clinically.  This will require a paradigm shift in how 456 
we traditionally approach veterinary medicine: 457 
1. We must improve how we record and collect clinical data.  We suffer in 458 
veterinary medicine with low patient numbers compared to human medicine 459 
and this is challenging when we need large cohorts of patients for specific 460 
studies.  With this, there will be a requirement for national and international 461 
collaboration, standardization of clinical recording, and significant 462 
investment in biobanking resources.  Some of these are being addressed in 463 
some part, but this will require significant funding and organization.  The 464 
concept of “Big Data” is being embraced by human medicine and, as a 465 
profession, if we are going to retain a competitive edge we must also embrace 466 
this. 467 
2. We must break down the discipline barriers and develop systems to handle 468 
large data sets.  This will involve developing systems that will allow us to 469 
integrate clinical, biological and epidemiological data to provide the optimum 470 
clinical care for our patients (precision medicine).  This may involve mapping 471 
a specific “comparative oncology ecosystem” that will provide the framework 472 
for interdisciplinarity and collaborative research. 473 
3. In embracing new technologies, we must also consider how we train the next 474 
generation of veterinarians to ensure they know how to interpret the 475 
potentially large amounts of data they will be able to generate from an 476 
individual patient. 477 
4. In the earlier years of the twentieth century, we relied up symptom 478 
recognition and application of knowledge.  Today, we are more in tune with 479 
pattern recognition and application of the evidence base.  Tomorrow, it is 480 
likely that we will embrace the acquisition of multiple levels of patient data 481 
(genome, to phenome) and apply that knowledge and information to 482 
treatment, but based up on specific algorithms derived from an evidence 483 
base.  This will herald the dawn of precision veterinary medicine (Figure 5). 484 
There is much cause for optimism in this arena as we are in the early stages of 485 
developing some of these systems to achieve this end goal.  Our challenge will be 486 
to work collaboratively and to ensure these approaches are adequately funded. 487 
 488 
Concluding remarks 489 
At the start of this synopsis, I painted a rather challenging view of cancer 490 
research and clinical oncology where complexity of this disease will constantly 491 
hinder progress.  However, I strongly believe that many of the hurdles that I have 492 
described can be overcome to the benefit of all species.  As a community, we 493 
must think far beyond the translation of basic biology into clinical practice, and 494 
consider the defining research and application that will truly transform clinical 495 
practice to the benefit of patients.  We have to remove the boundaries to 496 
research silos that are restricting progress and also the traditional species 497 
boundaries between human and veterinary oncology.  As an example, data 498 
science and large data set analysis will be vital to understanding the complexity 499 
of cancer at the cell and population level.  We will need to integrate clinical and 500 
biological data to improve treatment outcomes and design specific therapies.  501 
Precision medicine has been coined in human medicine as a model that proposes 502 
the customization of healthcare, with medical decisions, practices, and/or 503 
products being tailored to the individual patient.  It is possible, with new 504 
technologies that veterinary medicine will have to move in a similar direction.  505 
However, we have to embrace new technology and work collaboratively across 506 
disciplines to achieve this. 507 
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Figure Legends: 656 
 657 
Figure 1:  The Stochastic and Traditional Model of Cancer Development: This 658 
supports that a cell within the body sustain an “initiation” event, which 659 
causes a damage and change to the cell’s DNA (loss of gain of function of 660 
oncogenes or tumour suppressor genes).  In most cells receiving such 661 
damage, the cell would either die by programmed cell death or arrest so that 662 
the cell could repair it’s DNA.  In cell’s where this fails, they can accumulate 663 
genetic “hits” ultimately leading to the development of a cell with a malignant 664 
phenotype and the ability to metastasize. 665 
 666 
Figure 2: The Hallmarks of cancer as proposed by Hannah and Weinberg 667 
(adapted).  The model suggests that all cancers can be defined by the 668 
acquisition of 6 fundamental characteristics.  In 2011, altered metabolism 669 
and evasion of the immune system were also included as enabling 670 
characteristics of cancer cells. 671 
 672 
Figure 3: The stem cell model of cancer is not universally accepted and may 673 
be different for different cancer types.  In the model proposed in this 674 
diagram, an adult stem cell is the target cell, which receives the initial genetic 675 
“hit” or “hits” which allows “reprogramming of the cell” to a primitive 676 
phenotype (Tumour Initiating Cell or TIC).  This has been likened to the 677 
development if induced pluripotency in somatic cells in culture.  Once 678 
established the tumour resembles an organ structure in that the bulk of the 679 
tumour (Daughter Cancer Cells, DCCs) is driven by a very small population of 680 
cancer stem cells (CSC) that are capable of self-renewal.  There is also 681 
emerging evidence that there is considerable plasticity in these cells that 682 
contribute to supporting metastatic spread. 683 
  684 
Figure 4:  The tumour is subjected to intense Darwinian selection pressures, 685 
both in terms of selection of phenotypes resistant to drugs or cell death, but 686 
also refractory to immune surveillance.  Within this model, evolving tumour 687 
heterogeneity is compounded by cellular adaptation.  This results in a very 688 
complex problem for the development of treatments for cancer. 689 
 690 
Figure 5: The Development of Precision Veterinary Medicine.  In the earlier 691 
years of the twentieth century we relied upon symptom recognition and 692 
application of intuition.  Today, we are more in tune with pattern recognition 693 
and application of the evidence base.  Tomorrow, it is likely that we will 694 
embrace the acquisition of multiple levels of patient data (genome, to 695 
phenome) and apply that knowledge and information to treatment, but based 696 
up on specific algorithms derived from an evidence base.   697 
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Highlights for Review 
 
 Our understanding of cancer has increased exponentially in the past 25 
years 
 Our treatment of cancers in domestic animals has greatly improved 
 Our ability to generate data about cancer exceeds our capacity to analyse 
it 
 Much effort is needed to bring disciplines together to understand large 
data sets in cancer as they are too complex to be considered in isolation 
 As we move forward in veterinary medicine, we will become more reliant 
on ways to quickly assimilate data from multiple sources in order to make 
appropriate clinical judgements. 
*Highlights (for review)
